GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Abivax ABVX.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

77.70

+0.71%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−€336.1m

FY2016FY2025

Free cash flow

−€162.2m

FY2016FY2025

Shareholders' equity

€455.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue—€10.8m€4.6m€4.6m€37,000€14,000−€7,000€815,000€356,000€151,000
Gross profit−€1.1m€10.8m€4.5m€4.5m−€119,000−€52,000−€87,000−€14.6m−€10.1m−€14.5m
Research and development€177.8m€146.5m€103.2m€48.7m€47.2m€34.5m€29.0m€15.9m€10.8m€15.5m
Operating income−€250.6m−€185.4m−€133.9m−€53.8m−€52.2m−€37.8m−€33.3m−€19.4m−€14.2m−€18.2m
Net income−€336.1m−€176.2m−€147.7m−€60.7m−€42.5m−€37.6m−€30.6m−€15.8m−€11.2m−€14.3m
Diluted earnings per share-4.83-2.79-2.94-2.83-2.53-2.62-2.51-1.52-1.11-1.46

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets€584.3m€205.2m€327.1m€73.4m€110.4m€71.3m€51.7m€54.0m€53.8m€60.6m
Cash and short-term investments€530.4m€144.2m€261.0m€26.9m€60.7m€29.3m€9.8m€13.0m€17.0m€23.0m
Total liabilities€129.1m€164.6m€131.1m€71.5m€81.6m€66.6m€39.9m€19.4m€5.6m€3.9m
Debt€32.1m€97.4m€55.5m€39.2m€63.8m€39.5m€24.1m€12.0m€262,000€316,000
Shareholders' equity€455.2m€40.6m€196.0m€7.2m€28.8m€4.7m€11.8m€34.7m€48.2m€56.7m
Shares outstanding70m63m50m21m17m14m12m10m10m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−€162.1m−€154.1m−€97.1m−€65.6m−€45.7m−€29.8m−€27.5m−€14.6m−€8.4m−€15.6m
Capital spending−€142,000−€643,000−€265,000−€4.0m−€1.6m−€898,000−€941,000−€763,000−€979,000−€721,000
Free cash flow−€162.2m−€154.7m−€97.4m−€69.5m−€47.3m−€30.7m−€28.4m−€15.4m−€9.4m−€16.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——−€2.0m—€2.0m—€4.0m—
Gross profit——−€3.1m—€2.0m—€4.0m—
Operating income−€84.1m−€56.2m−€156.9m−€80.7m−€93.7m−€47.2m−€92.4m−€50.2m
Net income−€117.4m−€48.5m−€235.3m−€153.4m−€100.8m−€52.4m−€94.6m−€55.2m
Diluted earnings per share-1.47-0.61-3.38-2.21-1.45-0.75-1.50-0.87
Cash from operations−€51.0m−€50.0m−€71.0m−€71.0m−€66.0m−€33.0m−€70.0m−€35.0m
Total assets€462.2m€547.1m€584.3m€652.1m€119.6m€166.9m€205.2m—
Cash and short-term investments€410.7m—€530.4m—€60.9m€111.1m€144.2m—
Debt€1.1m—€29.4m€15.9m€84.6m€48.2m€96.2m—
Shareholders' equity€366.3m€429.6m€455.2m€511.2m−€48.3m−€6.6m€40.6m—

Financial ratios

Data as of 8 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin—100.0%97.2%98.5%-321.6%-371.4%1242.9%
Operating margin—-1564.0%-2897.9%-1173.9%-114462.2%-270057.1%475642.9%
Net margin—-1633.1%-3197.1%-1325.3%-114735.1%-268221.4%437628.6%
Return on equity-73.8%-434.3%-75.4%-844.9%-147.5%-803.6%—
Return on assets-57.5%-85.9%-45.2%-82.8%-38.5%-52.7%—
Free cash flow yield-3.0%-3.2%-2.5%-3.7%-3.4%-2.6%—
Revenue growth—133.5%0.8%12286.5%164.3%-300.0%-100.9%
Earnings growth90.7%19.3%143.2%43.1%13.1%22.6%—
Current ratio8.75x1.84x4.08x0.94x2.37x1.47x—
Debt to equity0.00x2.36x0.28x9.27x2.22x7.27x—
Equity ratio77.9%19.8%59.9%9.8%26.1%6.6%—
Interest coverage-8.79x-11.96x-9.69x-7.66x-11.90x-16.31x—
R&D as a share of sales—1357.8%2232.8%1063.2%127573.0%246614.3%-414385.7%
Buybacks as a share of market value-10.1%-25.7%-134.4%-27.9%-17.1%-17.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income67.0%46.0%29.9%
Net income76.9%55.0%35.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-24.9-2.4-3.3-2.2-11.3-13.1-9.0-7.8-7.8-4.3
Price to sales—39.6106.728.9——-39240.2151.6246.2409.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.